InnoCan Pharma (TSE:INNO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innocan Pharma has reported positive outcomes from a long-term compassionate therapy study where dogs with osteoarthritis experienced significant pain relief and mobility improvement after receiving liposomal-CBD (LPT-CBD) injections. The therapy could offer a non-opioid alternative for chronic pain management in animals, and potentially humans, with sustained effects lasting several weeks per dose.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.